GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » EPS without NRI

Eli Lilly and Co (Eli Lilly and Co) EPS without NRI

: $8.81 (TTM As of Dec. 2023)
View and export this data going back to 1970. Start your Free Trial

Eli Lilly and Co's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $2.49. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $8.81.

During the past 12 months, Eli Lilly and Co's average earnings per share (NRI) Growth Rate was -25.50% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 0.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 8.60% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 11.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Eli Lilly and Co's EPS without NRI or its related term are showing as below:

LLY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.4   Med: 12   Max: 80
Current: 0.8

During the past 13 years, Eli Lilly and Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 80.00% per year. The lowest was -27.40% per year. And the median was 12.00% per year.

LLY's 3-Year EPS without NRI Growth Rate is ranked worse than
65.35% of 834 companies
in the Drug Manufacturers industry
Industry Median: 11.35 vs LLY: 0.80

Eli Lilly and Co's EPS (Diluted) for the three months ended in Dec. 2023 was $2.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.69.

Eli Lilly and Co's EPS (Basic) for the three months ended in Dec. 2023 was $2.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.70.


Eli Lilly and Co EPS without NRI Historical Data

The historical data trend for Eli Lilly and Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.30 6.18 7.63 8.49 6.32

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.09 1.61 2.11 2.61 2.49

Competitive Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co PE Ratio without NRI Distribution

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's PE Ratio without NRI falls into.



Eli Lilly and Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eli Lilly and Co  (NYSE:LLY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Eli Lilly and Co EPS without NRI Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017

Eli Lilly and Co (Eli Lilly and Co) Headlines